Tolvaptan (Jynarque)
Small molecule
Evidence outlook
Approved: Autosomal Dominant Polycystic Kidney Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
- Jinarc: slow progression of cyst development and renal insufficiency in autosomal dominant polycystic kidney disease (CKD stage 1-3 at start, rapidly progressing)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00428948 NCT00428948 · Chronic Kidney Disease This was a large randomized, quadruple-blind, placebo-controlled trial of 1,445 people, and tolvaptan significantly slowed kidney growth compared with placebo. The primary endpoint, the yearly growth in total kidney volume measured on MRI, is an imaging marker of disease progression rather than a direct measure of how patients feel, function or survive, or of kidney function itself. Registry: NCT00428948 | 3 | Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36 2012-01 | Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results). | Partial signal | link ↗ |
View 1 more trial
NCT02160145 NCT02160145 · Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease This was a randomized, quadruple-blind, placebo-controlled trial in 1,370 patients, one of the largest studies of its kind in this disease. The primary endpoint, annualized change in kidney function (eGFR), showed significantly slower decline with tolvaptan than placebo (treatment difference 1.271 mL/min/1.73m^2/year, 95% CI 0.859 to 1.684, p<0.0001). Registry: NCT02160145 | 3 | The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up. (Pretreatment baseline to post-treatment follow-up (up to 61 weeks).) 2017-04-18 | Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001 | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other Vasopressin V2 receptor drugs
OPC-61815, Tolvaptan. Compare all 3 Vasopressin V2 receptor drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Autosomal Dominant Polycystic Kidney Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tolvaptan (Jynarque): this drug | Approved | Small molecule | Vasopressin V2 receptor | Partial signal | NCT02160145: Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001 NCT00428948: Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results). | |
| OPC-61815 (Samtasu) | Phase 3(overall) | Small molecule | Vasopressin V2 receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Tolvaptan (Samsca) | Phase 3(overall; approved for another use) | Small molecule | Vasopressin V2 receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| VX-407 | Phase 2 | Small molecule | Polycystin-1 (PKD1 variants) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1613 | Phase 1 | Monoclonal antibody | PAPP-A | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4771261 | Phase 1 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Farabursen | —(overall) | RNA / oligonucleotide | miR-17 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent